Cabot (CBT)
Search documents
Cabot (CBT) - 2023 Q3 - Earnings Call Transcript
2023-08-08 16:38
Financial Data and Key Metrics Changes - Adjusted earnings per share for Q3 2023 was $1.42, up 7% sequentially, but down from $1.73 in Q3 2022 [6][38] - The balance sheet remained strong with net debt to EBITDA at 1.7 times and total liquidity at $1.3 billion [7][17] - Discretionary free cash flow for the quarter was $128 million, with cash flow from operations at $243 million [17][21] Business Line Data and Key Metrics Changes - Reinforcement Materials achieved record EBIT of $132 million, up 17% year-over-year and 8% sequentially, despite an 8% decline in volumes [6][18] - Performance Chemicals saw EBIT decrease by $31 million year-over-year, driven by a 9% decline in volumes and lower unit margins [40] - Battery materials volumes increased by 29% sequentially and 50% year-over-year, reflecting recovery in the China EV market [12] Market Data and Key Metrics Changes - Year-to-date volumes in Reinforcement Materials were down 8%, primarily due to inventory destocking [8] - Manufacturing PMI levels in the U.S. and Europe remain below 50, indicating weak demand in industrial sectors [10] - The China EV market is recovering, but competitive intensity is increasing, impacting pricing and margins [12][35] Company Strategy and Development Direction - The company is focusing on market segmentation towards higher-performing batteries, particularly NCM chemistry, and managing the balance between volume and pricing [36][81] - The strategy emphasizes growth in North America and Europe, anticipating that these regions will comprise about 50% of the global battery market over the next decade [37][81] - The company aims to maintain a disciplined capital allocation strategy while returning cash to shareholders through dividends and share repurchases [19][69] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging macroeconomic environment with weak demand in key end markets, particularly in housing and construction [28][71] - The expectation is for adjusted earnings per share in Q4 to be in the range of $1.40 to $1.55, with strong cash flow anticipated [21][69] - Management expressed confidence that volumes will normalize post-destocking cycle, with a potential positive turn in demand expected [46][73] Other Important Information - The company raised its dividend by 8% in May and has returned $113 million to shareholders year-to-date [19] - The fiscal year operating tax rate increased from 25% to 28%, impacting adjusted earnings per share [39] - The company is recognized as a leader in sustainability, which underpins its strategic direction [72] Q&A Session All Questions and Answers Question: How long has the destock cycle lasted for replacement tires? - Management indicated that the current destock cycle appears more prolonged than historical patterns, with expectations of a positive turn as inventory levels normalize [46][73] Question: How are annual contract negotiations progressing? - Management believes price increases are necessary due to rising sustainability costs and expects that previous multi-year agreements will set the baseline for future contracts [48] Question: How much has the energy co-product credit declined due to lower oil prices? - The company noted a decline of approximately $20 million in energy center benefits for the full year 2023 compared to 2022 [51] Question: Are all carbon black producers reducing production similarly? - Management stated that volume declines are consistent with major tire producers, indicating stability in the market without significant share shifts [52] Question: Can you elaborate on the battery business outlook? - Management acknowledged a downward revision in EBITDA expectations for the battery business due to market dynamics in China and delays in ramping up volumes with Western customers [56][58] Question: What is the impact of Russian imports on the carbon black market? - Management indicated that Russian exports to Europe are down significantly and are expected to go to zero due to sanctions, with no material impact on competitive dynamics in China [114]
Cabot (CBT) - 2023 Q3 - Earnings Call Presentation
2023-08-08 12:28
CABOT EARNINGS TELECONFERENCE THIRD QUARTER – FISCAL 2023 CABOT Z This presentation contains forward-looking statements. All statements that address expectations or projections about the future, including with respect to our expectations for our performance in fiscal year 2023, including our expectations for adjusted earnings per share and the assumptions supporting our expectations, the factors that we expect will impact our results of operations, including for volumes in the fourth quarter of fiscal 2023 ...
Cabot (CBT) - 2023 Q3 - Quarterly Report
2023-08-07 16:00
Part I. Financial Information [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The unaudited consolidated financial statements for the quarterly period ended June 30, 2023, show a decrease in net sales and net income compared to the same period in 2022. Net sales for the third quarter were $968 million, down from $1,149 million year-over-year. Net income attributable to Cabot Corporation was $82 million for the quarter, compared to $97 million in the prior-year period. The balance sheet indicates total assets of $3,387 million as of June 30, 2023. Cash flow from operations for the nine months ended June 30, 2023, was a positive $457 million, a significant improvement from a $5 million use of cash in the prior-year period [Consolidated Statements of Operations](index=3&type=section&id=Consolidated%20Statements%20of%20Operations) For the third quarter ended June 30, 2023, Cabot reported Net Sales of $968 million, a decrease from $1,149 million in the same period of 2022. Net income attributable to Cabot Corporation was $82 million, or $1.43 per diluted share, compared to $97 million, or $1.69 per diluted share, in the prior-year quarter. For the nine-month period, net income increased to $211 million from $115 million year-over-year, primarily due to a large asset impairment charge in the prior year not recurring Consolidated Operations Summary | Financial Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Nine Months Ended June 30, 2023 | Nine Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | **Net sales and other operating revenues** | $968 million | $1,149 million | $2,966 million | $3,209 million | | **Gross profit** | $223 million | $235 million | $614 million | $665 million | | **Income from operations** | $150 million | $168 million | $384 million | $246 million | | **Net income attributable to Cabot** | $82 million | $97 million | $211 million | $115 million | | **Diluted Earnings per share** | $1.43 | $1.69 | $3.65 | $1.99 | [Consolidated Statements of Comprehensive Income (Loss)](index=4&type=section&id=Consolidated%20Statements%20of%20Comprehensive%20Income%20(Loss)) Comprehensive income attributable to Cabot Corporation was $67 million for the third quarter of 2023, a significant increase from $3 million in the same period of 2022. This was primarily driven by changes in foreign currency translation adjustments. For the nine-month period, comprehensive income was $321 million, compared to $36 million in the prior year, also largely due to favorable foreign currency translation adjustments Consolidated Comprehensive Income Summary | Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Nine Months Ended June 30, 2023 | Nine Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | **Net income (loss)** | $90 million | $106 million | $238 million | $140 million | | **Other comprehensive income (loss), net of tax** | ($21 million) | ($103 million) | $113 million | ($85 million) | | **Comprehensive income (loss) attributable to Cabot** | $67 million | $3 million | $321 million | $36 million | [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2023, Cabot's balance sheet showed total assets of $3,387 million, a slight decrease from $3,525 million at September 30, 2022. Total liabilities decreased to $2,121 million from $2,493 million over the same period. Total stockholders' equity increased to $1,266 million from $1,032 million, driven by net income Consolidated Balance Sheet Summary | Balance Sheet Item | June 30, 2023 (In millions) | September 30, 2022 (In millions) | | :--- | :--- | :--- | | **Total current assets** | $1,602 | $1,820 | | **Total assets** | $3,387 | $3,525 | | **Total current liabilities** | $738 | $1,105 | | **Total liabilities** | $2,121 | $2,493 | | **Total stockholders' equity** | $1,266 | $1,032 | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the nine months ended June 30, 2023, net cash provided by operating activities was $457 million, a significant turnaround from the $5 million used in the same period of 2022. Investing activities used $139 million, primarily for capital expenditures. Financing activities used $371 million, driven by net repayments of debt, dividends, and share repurchases. The company's cash and cash equivalents balance increased by $14 million to $220 million Consolidated Cash Flow Summary | Cash Flow Activity (Nine Months Ended June 30) | 2023 (In millions) | 2022 (In millions) | | :--- | :--- | :--- | | **Net cash provided (used) by operating activities** | $457 | ($5) | | **Net cash provided (used) by investing activities** | ($139) | ($31) | | **Net cash provided (used) by financing activities** | ($371) | $129 | | **Increase (decrease) in cash and cash equivalents** | $14 | $44 | | **Cash and cash equivalents at end of period** | $220 | $214 | [Notes to the Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20the%20Consolidated%20Financial%20Statements) The notes provide details on accounting policies, acquisitions, divestitures, contingencies, and segment information. Key items include the finalization of the Purification Solutions business sale, which resulted in an additional $3 million pre-tax loss. The company maintains a reserve of $38 million for respirator liabilities. A VAT matter was favorably resolved. Segment reporting shows Reinforcement Materials EBIT increased to $132 million in Q3 2023, while Performance Chemicals EBIT decreased to $32 million - In February 2022, the Company acquired Tokai Carbon (Tianjin) Co. for a net purchase price of **$9 million**, resulting in a gain on bargain purchase of **$24 million**[59](index=59&type=chunk) - The sale of the Purification Solutions business was finalized in Q1 fiscal 2023, resulting in an additional pre-tax loss on sale of **$3 million**[76](index=76&type=chunk) - The reserve for respirator liabilities was **$38 million** as of June 30, 2023, down slightly from **$39 million** at September 30, 2022[70](index=70&type=chunk) - A VAT-related legal matter was resolved favorably for the company in June 2023, making the possibility of a loss remote[71](index=71&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes the decrease in Q3 2023 revenue and earnings to lower volumes and unfavorable pricing, particularly in the Performance Chemicals segment, driven by demand softness and customer destocking. The Reinforcement Materials segment showed stronger results with higher unit margins from improved customer agreements. The company maintains a strong liquidity position with $220 million in cash and $1.1 billion in borrowing availability. Capital expenditures for fiscal 2023 are projected to be approximately $250 million [Results of Operations](index=22&type=section&id=Results%20of%20Operations) Consolidated net sales decreased by $181 million (15.8%) in Q3 2023 compared to Q3 2022, driven by lower volumes ($92 million) and unfavorable price/product mix ($56 million). Gross profit declined by $12 million due to lower volumes and higher fixed costs, partially offset by higher unit margins in Reinforcement Materials. Selling and administrative expenses increased due to a prior-year benefit from a land sale Results of Operations Summary | Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | | :--- | :--- | :--- | | **Net sales and other operating revenues** | $968 million | $1,149 million | | **Gross profit** | $223 million | $235 million | - The decrease in Q3 net sales was driven by lower volumes in both segments (**$92 million**), unfavorable price and product mix (**$56 million**), negative foreign currency impact (**$19 million**), and lower by-product revenue (**$8 million**)[116](index=116&type=chunk) [Segment Performance Analysis](index=26&type=section&id=Segment%20Performance%20Analysis) In Q3 2023, the Reinforcement Materials segment's EBIT increased by $19 million year-over-year to $132 million, driven by higher unit margins that offset lower volumes. Conversely, the Performance Chemicals segment's EBIT fell by $31 million to $32 million, primarily due to lower volumes from demand softness and reduced unit margins Segment Performance Summary | Segment (Q3 2023 vs Q3 2022) | Sales | EBIT | | :--- | :--- | :--- | | **Reinforcement Materials** | $624M vs $730M | $132M vs $113M | | **Performance Chemicals** | $307M vs $376M | $32M vs $63M | - Reinforcement Materials EBIT increased due to higher unit margins from favorable 2023 customer agreements, which more than offset lower volumes from reduced replacement tire demand[126](index=126&type=chunk)[131](index=131&type=chunk) - Performance Chemicals EBIT decreased due to lower volumes from demand softness in key end markets (especially fumed metal oxides) and less favorable product mix in specialty carbons and battery materials[55](index=55&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity position remains strong, with $220 million in cash and equivalents and $1.1 billion in borrowing availability as of June 30, 2023. Cash from operations for the first nine months of fiscal 2023 was $457 million, a significant improvement from the prior year. Capital expenditures for fiscal 2023 are expected to be approximately $250 million, focused on sustaining projects and capacity expansion in Performance Chemicals - As of June 30, 2023, the company had cash and cash equivalents of **$220 million** and borrowing availability of **$1.1 billion** under its revolving credit agreements[133](index=133&type=chunk) - Cash provided by operating activities totaled **$457 million** in the first nine months of fiscal 2023, compared to **$5 million** of cash used in the same period of fiscal 2022[136](index=136&type=chunk) - Projected capital expenditures for fiscal 2023 are approximately **$250 million**[140](index=140&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that information about market risks for the period ended June 30, 2023, does not differ materially from the disclosures provided in its Annual Report on Form 10-K for the fiscal year ended September 30, 2022 - There have been no material changes in market risk disclosures since the company's 2022 Form 10-K[43](index=43&type=chunk) [Item 4. Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Based on an evaluation as of June 30, 2023, the company's principal executive officer and principal financial officer concluded that the disclosure controls and procedures were effective. There were no material changes in internal controls over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2023[43](index=43&type=chunk) - No changes occurred during the fiscal quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[43](index=43&type=chunk) Part II. Other Information [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During the quarter ended June 30, 2023, Cabot repurchased a total of 212,161 shares of its common stock at an average price of approximately $70.70 per share. These purchases were made under a publicly announced repurchase plan authorized by the Board of Directors Share Repurchase Activity | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | May 1 - May 31, 2023 | 195,000 | $70.65 | | June 1 - June 30, 2023 | 17,161 | $71.30 | | **Total** | **212,161** | **~ $70.70** | - As of June 30, 2023, approximately **3.7 million shares** remained available for repurchase under the company's current authorization[47](index=47&type=chunk) [Item 5. Other Information](index=32&type=section&id=Item%205.%20Other%20Information) The company reported that during the fiscal quarter ended June 30, 2023, none of its directors or officers entered into, modified, or terminated any Rule 10b5-1 trading plans or non-Rule 10b5-1 trading arrangements - No directors or officers entered into, modified, or terminated Rule 10b5-1 trading plans during the quarter[47](index=47&type=chunk) [Item 6. Exhibits](index=33&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including the company's amended By-laws, amendments to credit agreements, and certifications by the Principal Executive Officer and Principal Financial Officer - Key exhibits filed include amended By-laws (Exhibit 3.2), amendments to credit agreements (Exhibits 10.1, 10.2), and officer certifications (Exhibits 31.1, 31.2, 32)[50](index=50&type=chunk)
Cabot (CBT) - 2023 Q2 - Earnings Call Transcript
2023-05-09 18:33
Cabot Corporation (NYSE:CBT) Q2 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Steve Delahunt - VP of IR & Treasurer Sean Keohane - President & CEO Erica McLaughlin - EVP, CFO and Head of Corporate Strategy Conference Call Participants John Roberts - Credit Suisse Dan Rizzo - Jefferies Chris Kapsch - Loop Capital Operator Thank you for standing by and Welcome to Cabot's Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After th ...
Cabot (CBT) - 2023 Q2 - Quarterly Report
2023-05-08 16:00
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Critical Accounting Policies Selling and administrative expenses decreased by $8 million and $19 million in the second quarter of fiscal 2023 and for the six months ended March 31, 2023, respectively, compared to the same periods of fiscal 2022, primarily due to a decrease in the accrual for incentive compensation in fiscal 2023 and costs associated with the Purification Solutions business in fiscal 2022 that did n ...
Cabot (CBT) - 2023 Q1 - Earnings Call Presentation
2023-02-10 16:00
CABOT EARNINGS TELECONFERENCE Forward Looking Statements Q1 FISCAL 2023 -------------- CABOTA | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------| | | | | | Q1 2023 Highlights | | | | First quarter results in line with expectations; adjusted EPS 1 of $0.98 and diluted EPS of $0.93 | | | | Reinforcement Materials segment EBIT of $94M; up 11% compa ...
Cabot (CBT) - 2023 Q1 - Earnings Call Transcript
2023-02-10 15:58
Cabot Corporation (NYSE:CBT) Q1 20232 Earnings Conference Call February 10, 2023 8:00 AM ET Company Participants Steve Delahunt - Vice President of Investor Relations & Treasurer Sean Keohane - President & Chief Executive Officer Erica McLaughlin - Executive Vice President, Chief Financial Officer and Head of Corporate Strategy Conference Call Participants David Begleiter - Deutsche Bank James Cannon - UBS Jeff Zekauskas - JPMorgan Dan Rizzo - Jefferies Chris Kapsch - Loop Capital Operator Ladies and gentle ...
Cabot (CBT) - 2023 Q1 - Quarterly Report
2023-02-08 16:00
Part I. Financial Information [Item 1. Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the unaudited consolidated financial statements of Cabot Corporation for the period ended December 31, 2022, including statements of operations, comprehensive income (loss), balance sheets, cash flows, changes in stockholders' equity, and detailed notes to the financial statements [Consolidated Statements of Operations](index=3&type=section&id=Consolidated%20Statements%20of%20Operations) Cabot Corporation reported a significant turnaround in net income for Q1 fiscal 2023, moving from a net loss of ($80) million in Q1 fiscal 2022 to a net income of $66 million. This was primarily driven by the absence of a large asset impairment charge related to the Purification Solutions divestiture that occurred in the prior year. Net sales remained relatively stable at $965 million compared to $968 million in the prior year, while gross profit decreased slightly | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :-------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Net sales and other operating revenues | $965 | $968 | | Cost of sales | $784 | $770 | | Gross profit | $181 | $198 | | Income (loss) from operations | $105 | ($83) | | Net income (loss) attributable to Cabot | $54 | ($89) | | Basic EPS | $0.94 | ($1.57) | | Diluted EPS | $0.93 | ($1.57) | [Consolidated Statements of Comprehensive Income (Loss)](index=4&type=section&id=Consolidated%20Statements%20of%20Comprehensive%20Income%20(Loss)) The company reported a comprehensive income of $153 million for Q1 fiscal 2023, a significant improvement from a comprehensive loss of ($108) million in Q1 fiscal 2022. This was largely influenced by a positive foreign currency translation adjustment of $88 million in the current period, contrasting with a ($28) million adjustment in the prior year | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :------------------------------------------------------------------ | :-------------------------------------------- | :-------------------------------------------- | | Net income (loss) | $66 | ($80) | | Foreign currency translation adjustment, net of tax | $88 | ($28) | | Other comprehensive income (loss), net of tax | $87 | ($28) | | Comprehensive income (loss) | $153 | ($108) | | Comprehensive income (loss) attributable to Cabot Corporation | $135 | ($119) | [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of December 31, 2022, Cabot Corporation's total assets stood at $3,535 million, a slight increase from $3,525 million at September 30, 2022. Total current assets decreased slightly, primarily due to lower accounts and notes receivable and cash, while total inventories increased. Total liabilities remained stable, and total stockholders' equity increased to $1,159 million from $1,032 million | Metric | December 31, 2022 (in millions) | September 30, 2022 (in millions) | | :-------------------------------------- | :------------------------------ | :------------------------------- | | Cash and cash equivalents | $190 | $206 | | Accounts and notes receivable, net | $779 | $836 | | Total inventories | $704 | $664 | | Total current assets | $1,800 | $1,820 | | Property, plant and equipment, net | $1,304 | $1,270 | | Total assets | $3,535 | $3,525 | | Total current liabilities | $984 | $1,105 | | Long-term debt | $1,091 | $1,089 | | Total stockholders' equity | $1,159 | $1,032 | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Cash provided by operating activities significantly improved to $52 million in Q1 fiscal 2023, compared to $49 million cash used in the same period of fiscal 2022. Investing activities consumed less cash, while financing activities shifted from providing cash to consuming cash, primarily due to commercial paper repayments and share repurchases | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :----------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Cash provided (used) by operating activities | $52 | ($49) | | Cash provided (used) by investing activities | ($17) | ($29) | | Cash provided (used) by financing activities | ($92) | $103 | | Increase (decrease) in cash, cash equivalents | ($16) | $10 | | Cash, cash equivalents at end of period | $190 | $180 | [Consolidated Statements of Changes in Stockholders' Equity](index=8&type=section&id=Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) Total Cabot Corporation stockholders' equity increased from $898 million at September 30, 2022, to $1,009 million at December 31, 2022. This increase was primarily driven by net income of $54 million and total other comprehensive income of $81 million, partially offset by cash dividends paid and share repurchases | Metric | Balance at Sep 30, 2022 (in millions) | Net Income (Loss) (in millions) | Total Other Comprehensive Income (Loss) (in millions) | Cash Dividends Paid (in millions) | Purchase and Retirement of Common Stock (in millions) | Balance at Dec 31, 2022 (in millions) | | :------------------------------------------ | :------------------------------------ | :------------------------------ | :---------------------------------------------------- | :-------------------------------- | :---------------------------------------------------- | :------------------------------------ | | Total Cabot Corporation Stockholders' Equity | $898 | $54 | $81 | ($21) | ($17) | $1,009 | - For the three months ended December 31, 2021, Total Cabot Corporation Stockholders' Equity decreased from **$947 million** to **$794 million**, primarily due to a net loss of **($89) million** and total other comprehensive loss of **($30) million**[79](index=79&type=chunk) [Notes to the Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20the%20Consolidated%20Financial%20Statements) The notes provide detailed information on the company's accounting policies, recent acquisitions and divestitures, goodwill and intangible assets, accumulated other comprehensive income, contingencies, insurance recoveries, income tax, earnings per share calculations, financial instruments, fair value measurements, and financial information by segment. Key changes include the finalization of Purification Solutions divestiture adjustments, an increase in goodwill due to foreign currency impact, and detailed segment performance [A. Basis of Presentation](index=10&type=section&id=A.%20Basis%20of%20Presentation) The consolidated financial statements are prepared in accordance with U.S. GAAP and include Cabot Corporation and its wholly-owned and majority-owned subsidiaries. The unaudited interim statements reflect all necessary normal recurring adjustments and should be read in conjunction with the 2022 10-K - The financial statements are unaudited and reflect all normal recurring adjustments[81](index=81&type=chunk) - They are prepared in conformity with U.S. GAAP and include Cabot Corporation and its subsidiaries[81](index=81&type=chunk) [B. Significant Accounting Policies](index=10&type=section&id=B.%20Significant%20Accounting%20Policies) The company's critical accounting policies have not substantially changed from the 2022 10-K. Recent accounting pronouncements include the FASB's Reference Rate Reform standard (no material impact), the Inflation Reduction Act (IRA) excise tax on stock repurchases (not anticipated to have a material effect), and a new standard on supplier financing programs (currently evaluating impact) - Critical accounting policies have not substantially changed from the 2022 10-K[11](index=11&type=chunk) - The Inflation Reduction Act (IRA) **1%** excise tax on stock repurchases, effective January 1, 2023, is not anticipated to have a material effect on financial statements or the share repurchase program[82](index=82&type=chunk) - The company is evaluating the impact of a new FASB standard on supplier financing programs, effective for fiscal years beginning after December 15, 2022[82](index=82&type=chunk) [C. Acquisition](index=10&type=section&id=C.%20Acquisition) In February 2022, Cabot Corporation acquired 100% of Tokai Carbon (Tianjin) Co., a carbon black manufacturing facility, for a net purchase price of $9 million - Acquisition of Tokai Carbon (Tianjin) Co. in February 2022 for a net purchase price of **$9 million**[83](index=83&type=chunk) [D. Divestitures](index=11&type=section&id=D.%20Divestitures) The sale of the Purification Solutions business, completed in March 2022, resulted in an additional pre-tax loss on sale of $3 million in Q1 fiscal 2023, following a $197 million impairment charge and $10 million loss on sale in fiscal 2022 - Finalized post-closing adjustments for the Purification Solutions business sale resulted in an additional pre-tax loss on sale of **$3 million** in Q1 fiscal 2023[84](index=84&type=chunk) - The divestiture had previously resulted in a **$197 million** pre-tax impairment charge and a **$10 million** pre-tax loss on sale in fiscal 2022[84](index=84&type=chunk) [E. Goodwill and Intangible Assets](index=11&type=section&id=E.%20Goodwill%20and%20Intangible%20Assets) Goodwill increased by $4 million to $133 million as of December 31, 2022, primarily due to foreign currency impact. Intangible assets are amortized over 10-25 years, with an estimated $6 million annual amortization expense for the next five fiscal years | Segment | Balance at Sep 30, 2022 (in millions) | Foreign Currency Impact (in millions) | Balance at Dec 31, 2022 (in millions) | | :---------------------- | :------------------------------------ | :------------------------------------ | :------------------------------------ | | Reinforcement Materials | $46 | $2 | $48 | | Performance Chemicals | $83 | $2 | $85 | | Total | $129 | $4 | $133 | - Amortization expense for intangible assets was **$1 million** in Q1 fiscal 2023, down from **$2 million** in Q1 fiscal 2022[85](index=85&type=chunk) - Estimated total amortization expense is approximately **$6 million** each year for the next five fiscal years[85](index=85&type=chunk) [F. Accumulated Other Comprehensive Income (Loss) ("AOCI")](index=12&type=section&id=F.%20Accumulated%20Other%20Comprehensive%20Income%20(Loss)%20(%22AOCI%22)) AOCI attributable to Cabot Corporation improved from ($439) million at September 30, 2022, to ($358) million at December 31, 2022, primarily due to an $88 million positive currency translation adjustment | Metric | Balance at Sep 30, 2022 (in millions) | Other Comprehensive Income (Loss) before Reclassifications (in millions) | Amounts Reclassified from AOCI (in millions) | Less: Other Comprehensive Income (Loss) Attributable to Noncontrolling Interests (in millions) | Balance at Dec 31, 2022 (in millions) | | :------------------------------------------------------------------ | :------------------------------------ | :----------------------------------------------------------------------- | :------------------------------------------- | :----------------------------------------------------------------------------------------------- | :------------------------------------ | | Balance at September 30, 2022, attributable to Cabot Corporation | ($439) | | | | | | Other comprehensive income (loss) before reclassifications | | $88 | | | | | Amounts reclassified from AOCI | | | ($1) | | | | Less: Other comprehensive income (loss) attributable to noncontrolling interests | | | | $6 | | | Balance at December 31, 2022, attributable to Cabot Corporation | | | | | ($358) | - AOCI attributable to Cabot Corporation improved by **$81 million**, from **($439) million** at September 30, 2022, to **($358) million** at December 31, 2022, largely driven by an **$88 million** positive currency translation adjustment[71](index=71&type=chunk) [G. Contingencies](index=12&type=section&id=G.%20Contingencies) Cabot maintains a $39 million reserve for respirator liability claims, which remained unchanged from September 30, 2022, to December 31, 2022. The company continues to monitor the Aearo Technologies bankruptcy proceedings, a member of the Payor Group, for potential impacts on its liability. Litigation outcomes are inherently unpredictable, and changes in estimates could be material - Cabot has a reserve of **$39 million** for respirator liability claims as of December 31, 2022, unchanged from September 30, 2022[72](index=72&type=chunk) - The company is monitoring the Chapter 11 bankruptcy of Aearo Technologies, a member of the Payor Group, for potential impacts on its respirator liability[72](index=72&type=chunk) - It is reasonably possible that liabilities for existing and future claims could change materially in the near term due to various factors[73](index=73&type=chunk) [H. Insurance Recoveries](index=13&type=section&id=H.%20Insurance%20Recoveries) In Q1 fiscal 2023, Cabot received $6 million in insurance proceeds related to the July 2021 Pepinster, Belgium flood, recognizing a $5 million gain and $1 million loss recovery. This contrasts with Q1 fiscal 2022, where $5 million in flood-related expenses were fully offset by expected insurance recoveries - Received **$6 million** in insurance proceeds in Q1 fiscal 2023 related to the Pepinster, Belgium flood, recognizing a **$5 million** gain and **$1 million** loss recovery[105](index=105&type=chunk) - In Q1 fiscal 2022, **$5 million** in flood-related expenses were recorded and fully offset by expected insurance recoveries[105](index=105&type=chunk) [I. Income Tax](index=13&type=section&id=I.%20Income%20Tax) The provision for income taxes was $20 million in Q1 fiscal 2023, compared to a $12 million benefit in Q1 fiscal 2022. This change was primarily due to higher earnings in the current period and the non-recurring nature of a $37 million discrete tax benefit in the prior year related to the Purification Solutions divestiture. The company released $1 million in uncertain tax positions in both periods due to statute of limitations expirations | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :----------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | (Provision) benefit for income taxes | ($20) | $12 | - Q1 fiscal 2023 included a net discrete tax expense of **$3 million**, while Q1 fiscal 2022 included a net discrete tax benefit of **$37 million** after valuation allowance, related to the Purification Solutions business divestiture and asset impairment charge[91](index=91&type=chunk) - Cabot released **$1 million** in uncertain tax positions in both Q1 fiscal 2023 and Q1 fiscal 2022 due to the expiration of statutes of limitations[93](index=93&type=chunk) [J. Earnings Per Share](index=14&type=section&id=J.%20Earnings%20Per%20Share) Basic EPS was $0.94 and diluted EPS was $0.93 for Q1 fiscal 2023, a significant improvement from ($1.57) for both basic and diluted EPS in Q1 fiscal 2022. This increase was primarily due to higher net income attributable to Cabot Corporation | Metric | Three Months Ended Dec 31, 2022 | Three Months Ended Dec 31, 2021 | | :------------------------------------------------------------------ | :------------------------------ | :------------------------------ | | Net income (loss) attributable to Cabot Corporation (in millions) | $54 | ($89) | | Earnings (loss) per common share - basic | $0.94 | ($1.57) | | Earnings (loss) per common share - diluted | $0.93 | ($1.57) | | Weighted average common shares outstanding - basic (in millions) | 56.3 | 56.8 | | Weighted average common shares outstanding - diluted (in millions) | 56.7 | 56.8 | - Incremental shares of common stock from assumed exercise of stock options were excluded from diluted EPS calculation if antidilutive (**86,782 shares** in Q1 FY23, **2,356,941 shares** in Q1 FY22)[94](index=94&type=chunk) [K. Financial Instruments and Fair Value Measurements](index=15&type=section&id=K.%20Financial%20Instruments%20and%20Fair%20Value%20Measurements) The company classifies financial assets and liabilities into a fair value hierarchy. Cash and cash equivalents, accounts receivable/payable, and short-term borrowings are Level 1. Derivatives (foreign currency risks) and guaranteed investment contracts are Level 2, with fair values of $15 million and $9 million respectively as of December 31, 2022. Long-term fixed rate debt fair value was $1.06 billion, approximating its carrying value of $1.08 billion - Fair values of cash and cash equivalents, accounts and notes receivable, accounts payable and accrued liabilities, and short-term borrowings approximate their carrying values and are classified as Level 1[95](index=95&type=chunk) - Derivatives relating to foreign currency risks (net asset of **$15 million**) and guaranteed investment contracts (asset of **$9 million**) are classified as Level 2 instruments as of December 31, 2022[109](index=109&type=chunk) - The fair value of long-term fixed rate debt was **$1.06 billion**, approximating its carrying value of **$1.08 billion**, classified as Level 2[109](index=109&type=chunk) [L. Financial Information by Segment](index=16&type=section&id=L.%20Financial%20Information%20by%20Segment) Cabot Corporation operates with two reportable segments: Reinforcement Materials and Performance Chemicals, following the divestiture of Purification Solutions in fiscal 2022. Segment EBIT is used by the CODM to evaluate performance and allocate resources, excluding certain items and unallocated corporate costs [Segment Definition](index=16&type=section&id=Segment%20Definition) Operating segments are identified based on business activities, CODM review, and discrete financial information. They are aggregated into reportable segments if they have similar economic characteristics, products, production processes, customer types, and distribution methods. Cabot's two reportable segments are Reinforcement Materials and Performance Chemicals - Operating segments are aggregated into reportable segments if they have similar economic characteristics, nature of products and services, production processes, customer class, and product distribution methods[6](index=6&type=chunk) - The Reinforcement Materials segment combines reinforcing carbons and engineered elastomer composites product lines[6](index=6&type=chunk) - The Performance Chemicals segment aggregates specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines[6](index=6&type=chunk) [Segment Results](index=16&type=section&id=Segment%20Results) In Q1 fiscal 2023, Reinforcement Materials sales increased to $643 million (from $563 million in Q1 FY22) and EBIT increased to $94 million (from $85 million). Performance Chemicals sales decreased to $286 million (from $306 million) and EBIT decreased to $29 million (from $52 million). Unallocated and Other income (loss) before income taxes improved significantly from ($230) million to ($39) million, largely due to the absence of prior year's divestiture-related charges | Segment | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :------------------------ | :-------------------------------------------- | :-------------------------------------------- | | Reinforcement Materials Sales | $643 | $563 | | Reinforcement Materials EBIT | $94 | $85 | | Performance Chemicals Sales | $286 | $306 | | Performance Chemicals EBIT | $29 | $52 | | Purification Solutions Sales | $0 | $61 | | Purification Solutions EBIT | $0 | $0 | | Unallocated and Other Income (loss) before income taxes | ($39) | ($230) | - Unallocated and Other income (loss) before income taxes improved significantly due to the absence of a **$197 million** loss on sale of business and asset impairment charge in the prior year[9](index=9&type=chunk) [Geographic Revenues](index=18&type=section&id=Geographic%20Revenues) For Q1 fiscal 2023, Americas contributed $330 million to consolidated total revenues, Asia Pacific $399 million, and Europe, Middle East and Africa $200 million. This shows a shift in regional contribution compared to Q1 fiscal 2022, where Asia Pacific was the largest contributor at $395 million, followed by Americas at $326 million | Region | Reinforcement Materials (in millions) | Performance Chemicals (in millions) | Consolidated Total (in millions) | | :------------------------- | :------------------------------------ | :---------------------------------- | :------------------------------- | | Americas | $241 | $89 | $330 | | Asia Pacific | $273 | $126 | $399 | | Europe, Middle East and Africa | $129 | $71 | $200 | | Segment revenues from external customers | $643 | $286 | $929 | | Region | Reinforcement Materials (in millions) | Performance Chemicals (in millions) | Purification Solutions (in millions) | Consolidated Total (in millions) | | :------------------------- | :------------------------------------ | :---------------------------------- | :----------------------------------- | :------------------------------- | | Americas | $209 | $90 | $27 | $326 | | Asia Pacific | $250 | $137 | $8 | $395 | | Europe, Middle East and Africa | $104 | $79 | $26 | $209 | | Segment revenues from external customers | $563 | $306 | $61 | $930 | - Cabot has two reportable segments: Reinforcement Materials and Performance Chemicals. The Purification Solutions business was a separate reporting segment prior to divestiture in Q2 fiscal 2022[6](index=6&type=chunk) - Segment EBIT for Reinforcement Materials increased to **$94 million** in Q1 FY23 from **$85 million** in Q1 FY22[97](index=97&type=chunk) - Segment EBIT for Performance Chemicals decreased to **$29 million** in Q1 FY23 from **$52 million** in Q1 FY22[97](index=97&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the company's financial performance, liquidity, and capital resources for the first quarter of fiscal 2023 compared to the prior year. It details the drivers behind changes in consolidated and segment-level results, including the impact of divestitures, foreign currency, pricing, volumes, and operational costs. It also discusses critical accounting policies, recent accounting pronouncements, and forward-looking information [Critical Accounting Policies](index=20&type=section&id=Critical%20Accounting%20Policies) The company states that its critical accounting policies have not substantially changed from those described in the 2022 10-K - Critical accounting policies have not substantially changed from the 2022 10-K[11](index=11&type=chunk) [Recently Issued Accounting Pronouncements](index=20&type=section&id=Recently%20Issued%20Accounting%20Pronouncements) This section refers to Note B of the Consolidated Financial Statements for details on recently issued accounting pronouncements, which include the FASB's Reference Rate Reform, the Inflation Reduction Act, and a new standard on supplier financing programs - Refer to the discussion under the heading "Recent Accounting Pronouncements" in Note B of the Notes to the Consolidated Financial Statements[112](index=112&type=chunk) [Overview](index=21&type=section&id=Overview) Income (loss) before income taxes and equity in earnings of affiliated companies increased in Q1 fiscal 2023 compared to Q1 fiscal 2022. This increase was primarily due to the non-recurrence of a $197 million impairment charge related to the Purification Solutions divestiture in fiscal 2022, partially offset by decreased earnings in the Performance Chemicals segment in fiscal 2023 - Income (loss) before income taxes and equity in earnings of affiliated companies increased in Q1 fiscal 2023 compared to Q1 fiscal 2022[12](index=12&type=chunk) - The increase was driven by an impairment charge related to the divestiture of Purification Solutions of **$197 million** in fiscal 2022 that did not repeat in fiscal 2023[12](index=12&type=chunk) - This was partially offset by decreased earnings in the fiscal 2023 period in our Performance Chemicals segment[12](index=12&type=chunk) [First quarter of Fiscal 2023 versus First quarter of Fiscal 2022—Consolidated](index=21&type=section&id=First%20quarter%20of%20Fiscal%202023%20versus%20First%20quarter%20of%20Fiscal%202022%E2%80%94Consolidated) Consolidated results for Q1 fiscal 2023 showed a slight decrease in net sales and gross profit compared to Q1 fiscal 2022. However, net income attributable to Cabot Corporation significantly improved due to the absence of a prior-year impairment charge. Interest expense increased, while selling and administrative expenses decreased [Net Sales and Other Operating Revenues and Gross Profit](index=21&type=section&id=Net%20Sales%20and%20Other%20Operating%20Revenues%20and%20Gross%20Profit) Net sales and other operating revenues decreased by $3 million in Q1 fiscal 2023 compared to Q1 fiscal 2022, primarily due to unfavorable foreign currency translation ($73 million), the divestiture of Purification Solutions ($61 million), and lower volumes ($42 million). These declines were largely offset by favorable price and product mix ($177 million). Gross profit decreased by $17 million due to lower volumes and higher fixed costs, partially offset by higher unit margins | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :-------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Net sales and other operating revenues | $965 | $968 | | Gross profit | $181 | $198 | - The **$3 million** decrease in net sales and other operating revenues was driven by unfavorable foreign currency translation (**$73 million**), the divestiture of Purification Solutions (**$61 million**), and lower volumes (**$42 million**)[26](index=26&type=chunk) - These decreases were largely offset by favorable price and product mix (combined **$177 million**)[26](index=26&type=chunk) [Selling and Administrative Expenses](index=21&type=section&id=Selling%20and%20Administrative%20Expenses) Selling and administrative expenses decreased by $11 million in Q1 fiscal 2023 compared to Q1 fiscal 2022, primarily due to the non-recurrence of costs associated with the Purification Solutions business from the prior year | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :-------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Selling and administrative expenses | $60 | $71 | - Selling and administrative expenses decreased by **$11 million** primarily due to costs associated with the Purification Solutions business in fiscal 2022 that did not reoccur in fiscal 2023[131](index=131&type=chunk) [Research and Technical Expenses](index=22&type=section&id=Research%20and%20Technical%20Expenses) Research and technical expenses remained flat at $13 million in Q1 fiscal 2023 compared to the same period in fiscal 2022 | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :-------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Research and technical expenses | $13 | $13 | [Interest and Dividend Income, Interest Expense and Other Income (Expense)](index=22&type=section&id=Interest%20and%20Dividend%20Income,%20Interest%20Expense%20and%20Other%20Income%20(Expense)) Interest and dividend income increased by $3 million in Q1 fiscal 2023 due to higher interest rates. Interest expense increased by $10 million, also due to higher interest rates on borrowings. Other expense increased by $4 million, primarily due to foreign currency losses in Argentina | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Interest and dividend income | $6 | $3 | | Interest expense | ($22) | ($12) | | Other income (expense) | ($5) | ($1) | - Interest and dividend income increased by **$3 million** primarily due to higher interest rates[14](index=14&type=chunk) - Interest expense increased by **$10 million** primarily due to higher interest rates on borrowings under commercial paper program and unsecured notes issued in June 2022[14](index=14&type=chunk) - Other expense increased by **$4 million** primarily due to foreign currency losses on revaluation of balance sheet exposures, primarily in Argentina[14](index=14&type=chunk) [(Provision) Benefit for Income Taxes and Reconciliation of Effective Tax Rate to Operating Tax Rate](index=23&type=section&id=(Provision)%20Benefit%20for%20Income%20Taxes%20and%20Reconciliation%20of%20Effective%20Tax%20Rate%20to%20Operating%20Tax%20Rate) The provision for income taxes was $20 million in Q1 fiscal 2023, compared to a $12 million benefit in Q1 fiscal 2022, primarily due to higher earnings and the non-recurring nature of a prior-year impairment charge. The effective tax rate was 24% in Q1 FY23, compared to 13% in Q1 FY22. The operating tax rate for fiscal 2023 is expected to be in the range of 24% to 26% | Metric | Three Months Ended Dec 31, 2022 (in millions) | Rate | Three Months Ended Dec 31, 2021 (in millions) | Rate | | :-------------------------------------- | :-------------------------------------------- | :------ | :-------------------------------------------- | :------ | | Effective tax rate | ($20) | 24 % | $12 | 13 % | | Less: Non-GAAP tax adjustments | $1 | | $42 | | | Operating tax rate | ($21) | 25 % | ($30) | 27 % | - The (Provision) benefit for income taxes was a provision of **$20 million** in Q1 FY23, compared to a **$12 million** benefit in Q1 FY22, primarily due to higher earnings and the non-recurring nature of an impairment charge related to the divestiture of the Purification Solutions business[115](index=115&type=chunk) - For fiscal 2023, the Operating tax rate is expected to be in the range of **24%** to **26%**[115](index=115&type=chunk) [Equity in earnings of affiliated companies, net of tax](index=23&type=section&id=Equity%20in%20earnings%20of%20affiliated%20companies,%20net%20of%20tax) Equity in earnings of affiliated companies, net of tax, increased by $1 million in Q1 fiscal 2023, primarily due to higher profitability at equity affiliates in India and Venezuela | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :---------------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Equity in earnings of affiliated companies, net of tax | $2 | $1 | - Equity in earnings of affiliated companies, net of tax, increased by **$1 million** primarily due to higher profitability at our equity affiliates in India and Venezuela[104](index=104&type=chunk) [Net Income (Loss) Attributable to Noncontrolling Interests](index=23&type=section&id=Net%20Income%20(Loss)%20Attributable%20to%20Noncontrolling%20Interests) Net income attributable to noncontrolling interests, net of tax, increased by $3 million in Q1 fiscal 2023, primarily due to higher profitability of the joint venture in the Czech Republic | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :---------------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Net income (loss) attributable to noncontrolling interests, net of tax | $12 | $9 | - Net income (loss) attributable to noncontrolling interests, net of tax, increased by **$3 million** primarily due to higher profitability of our joint venture in the Czech Republic[104](index=104&type=chunk) [Net Income Attributable to Cabot Corporation](index=23&type=section&id=Net%20Income%20Attributable%20to%20Cabot%20Corporation) Net income attributable to Cabot Corporation was $54 million ($0.93 diluted EPS) in Q1 fiscal 2023, a significant improvement from a net loss of ($89) million (($1.57) diluted EPS) in Q1 fiscal 2022. This was primarily due to the non-recurrence of an impairment charge related to the Purification Solutions divestiture in the prior year - Net income (loss) attributable to Cabot Corporation was **$54 million**, or **$0.93** per diluted common share, in Q1 fiscal 2023, compared to **($89) million**, or **($1.57)** per diluted common share, in Q1 fiscal 2022[116](index=116&type=chunk) - The higher net income in Q1 fiscal 2023 was primarily due to an impairment charge associated with the divestiture of Purification Solutions in fiscal 2022 that did not reoccur in fiscal 2023[116](index=116&type=chunk) [First quarter of Fiscal 2023 versus First quarter of Fiscal 2022—By Business Segment](index=24&type=section&id=First%20quarter%20of%20Fiscal%202023%20versus%20First%20quarter%20of%20Fiscal%202022%E2%80%94By%20Business%20Segment) Total segment EBIT decreased by $14 million in Q1 fiscal 2023, primarily due to lower volumes in both Reinforcement Materials and Performance Chemicals segments, driven by year-end customer destocking and COVID-19 impacts in China. Income (loss) before income taxes and equity in earnings of affiliated companies increased significantly due to the non-recurrence of a large impairment charge from the prior year [Total Segment EBIT Reconciliation](index=24&type=section&id=Total%20Segment%20EBIT%20Reconciliation) Total segment EBIT decreased by $14 million to $123 million in Q1 fiscal 2023 from $137 million in Q1 fiscal 2022. This was primarily due to lower volumes across segments. Income (loss) before income taxes and equity in earnings of affiliated companies increased by $177 million, largely due to the non-recurrence of a $197 million impairment charge related to the Purification Solutions divestiture in fiscal 2022 | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :------------------------------------------------------------------ | :-------------------------------------------- | :-------------------------------------------- | | Income (loss) before income taxes and equity in earnings of affiliated companies | $84 | ($93) | | Less: Certain items | ($4) | ($204) | | Less: Other unallocated items | ($35) | ($26) | | Total segment EBIT | $123 | $137 | - Income (loss) before income taxes and equity in earnings of affiliated companies increased by **$177 million**, largely driven by an impairment charge of **$197 million** related to the sale of the Purification Solutions business in fiscal 2022 that did not reoccur in fiscal 2023[135](index=135&type=chunk) - The decrease in Total segment EBIT was driven by lower volumes in both the Reinforcement Materials and Performance Chemicals segments (combined **$21 million**), due to year-end customer destocking and the impact of COVID-19 outbreaks in China[135](index=135&type=chunk) [Certain Items](index=24&type=section&id=Certain%20Items) Certain items, which management does not consider representative of ongoing operating segment results, totaled ($4) million pre-tax in Q1 fiscal 2023, a significant improvement from ($204) million pre-tax in Q1 fiscal 2022. This improvement was primarily due to the absence of the large loss on sale of business and asset impairment charge from the prior year | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :------------------------------------------ | :-------------------------------------------- | :-------------------------------------------- | | Loss on sale of business and asset impairment charge | ($3) | ($197) | | Total certain items, pre-tax | ($4) | ($204) | | Total certain items, after tax | ($3) | ($162) | - The significant reduction in certain items was due to the non-recurrence of the **$197 million** loss on sale of business and asset impairment charge from Q1 FY22[17](index=17&type=chunk) [Other Unallocated Items](index=24&type=section&id=Other%20Unallocated%20Items) Other unallocated items, which are not controlled by business segments and primarily benefit corporate objectives, increased to ($35) million in Q1 fiscal 2023 from ($26) million in Q1 fiscal 2022. This increase was mainly driven by higher interest expense | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :------------------------------------------ | :-------------------------------------------- | :-------------------------------------------- | | Interest expense | ($22) | ($12) | | Unallocated corporate costs | ($15) | ($14) | | General unallocated income (expense) | $4 | $1 | | Less: Equity in earnings of affiliated companies, net of tax | $2 | $1 | | Total other unallocated items | ($35) | ($26) | - The increase in total other unallocated items was primarily due to higher interest expense[17](index=17&type=chunk) [Reinforcement Materials](index=25&type=section&id=Reinforcement%20Materials) Reinforcement Materials sales increased by $80 million to $643 million in Q1 fiscal 2023, driven by a favorable price and product mix ($161 million), partially offset by unfavorable foreign currency translation ($51 million) and lower volumes ($28 million). EBIT increased by $9 million to $94 million, primarily due to higher unit margins ($36 million), despite lower volumes, higher fixed costs, and unfavorable foreign currency exchange | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :-------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Reinforcement Materials Sales | $643 | $563 | | Reinforcement Materials EBIT | $94 | $85 | - Sales increase driven by a favorable price and product mix (combined **$161 million**), partially offset by unfavorable foreign currency translation (**$51 million**) and lower volumes (**$28 million**)[136](index=136&type=chunk) - EBIT increase driven by higher unit margins (**$36 million**), partially offset by **5% lower volumes** (**$10 million**), higher fixed costs (**$11 million**), and unfavorable foreign currency exchange (**$5 million**)[136](index=136&type=chunk) [Performance Chemicals](index=25&type=section&id=Performance%20Chemicals) Performance Chemicals sales decreased by $20 million to $286 million in Q1 fiscal 2023, primarily due to unfavorable foreign currency translation ($22 million) and lower volumes ($13 million), partially offset by favorable price and product mix ($16 million). EBIT decreased by $23 million to $29 million, mainly due to lower volumes ($11 million), higher fixed costs ($8 million), and unfavorable foreign currency exchange ($4 million) | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :-------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Performance Chemicals Sales | $286 | $306 | | Performance Chemicals EBIT | $29 | $52 | - Sales decreased primarily due to unfavorable foreign currency translation (**$22 million**) and lower volumes (**$13 million**), partially offset by favorable price and product mix (combined **$16 million**)[18](index=18&type=chunk) - EBIT decreased primarily due to lower volumes (**$11 million**), higher fixed costs (**$8 million**), and the unfavorable impact from foreign currency exchange (**$4 million**)[18](index=18&type=chunk) [Purification Solutions](index=25&type=section&id=Purification%20Solutions) The Purification Solutions business was divested in March 2022, and therefore reported no sales or EBIT in Q1 fiscal 2023, compared to $61 million in sales and no EBIT in Q1 fiscal 2022 - The Purification Solutions business was divested in March 2022[120](index=120&type=chunk) | Metric | Three Months Ended Dec 31, 2022 (in millions) | Three Months Ended Dec 31, 2021 (in millions) | | :-------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Purification Solutions Sales | $0 | $61 | | Purification Solutions EBIT | $0 | $0 | [Liquidity and Capital Resources](index=26&type=section&id=Liquidity%20and%20Capital%20Resources) Cabot's liquidity position increased by $57 million in Q1 fiscal 2023, with $190 million in cash and cash equivalents and $930 million in borrowing availability. The company anticipates sufficient liquidity from cash on hand, operating activities, and credit agreements to meet future needs [Overview](index=26&type=section&id=Overview) Cabot's liquidity position increased by $57 million in Q1 fiscal 2023, reaching $190 million in cash and cash equivalents and $930 million in borrowing availability under its credit agreements as of December 31, 2022. The company expects sufficient liquidity from these sources and operating cash flows to meet future operational and capital needs - Liquidity position, as measured by cash and cash equivalents plus borrowing availability, increased by **$57 million** during the first three months of fiscal 2023[120](index=120&type=chunk) - As of December 31, 2022, cash and cash equivalents were **$190 million** and borrowing availability under revolving credit agreements was **$930 million**[120](index=120&type=chunk) - The company anticipates sufficient liquidity from cash on hand, cash flows from operating activities, and cash available from Credit Agreements and commercial paper program to meet operational and capital investment needs and financial obligations for the foreseeable future[20](index=20&type=chunk) [Cash Flows from Operating Activities](index=26&type=section&id=Cash%20Flows%20from%20Operating%20Activities) Cash provided by operating activities was $52 million in Q1 fiscal 2023, a significant improvement from $49 million cash used in Q1 fiscal 2022. This was driven by business earnings (excluding non-cash items) partially offset by an increase in net working capital due to a decrease in accounts payable and accrued expenses - Cash provided by operating activities totaled **$52 million** in the first three months of fiscal 2023 compared to **$49 million** of cash used by operating activities during the same period of fiscal 2022[20](index=20&type=chunk) - Cash provided by operating activities in Q1 FY23 was driven by business earnings (excluding non-cash impacts of depreciation and amortization of **$35 million**), partially offset by an increase in net working capital of **$34 million**[34](index=34&type=chunk) - The increase in net working capital was largely driven by a decrease in accounts payable and accrued expenses, partially offset by a decrease in accounts receivables[34](index=34&type=chunk) [Cash Flows from Investing Activities](index=27&type=section&id=Cash%20Flows%20from%20Investing%20Activities) Investing activities consumed $17 million of cash in Q1 fiscal 2023, down from $29 million in Q1 fiscal 2022. This included $35 million in capital expenditures, partially offset by $7 million from land sales, $6 million from the Purification Solutions business sale, and $6 million from insurance settlements. Capital expenditures for fiscal 2023 are projected to be approximately $300 million - Investing activities consumed **$17 million** of cash in the first three months of fiscal 2023 compared to **$29 million** in the first three months of fiscal 2022[122](index=122&type=chunk) - Q1 FY23 investing activities included **$35 million** of capital expenditures, partially offset by proceeds from the sale of land of **$7 million**, proceeds from the sale of Purification Solutions business of **$6 million**, and proceeds from insurance settlements of **$6 million**[122](index=122&type=chunk) - Capital expenditures for fiscal 2023 are expected to be approximately **$300 million**, primarily for sustaining, compliance, improvement capital projects, and capacity expansion in the Performance Chemicals segment[122](index=122&type=chunk) [Cash Flows from Financing Activities](index=27&type=section&id=Cash%20Flows%20from%20Financing%20Activities) Financing activities consumed $92 million of cash in Q1 fiscal 2023, a shift from providing $103 million in Q1 fiscal 2022. This was primarily due to $48 million in commercial paper repayments, $21 million in common stock dividends, $17 million in share repurchases, and $14 million in noncontrolling interest dividends - Financing activities consumed **$92 million** of cash in the first three months of fiscal 2023 compared to **$103 million** of cash provided during the same period of fiscal 2022[122](index=122&type=chunk) - Q1 FY23 financing activities primarily consisted of the repayment of commercial paper of **$48 million**, dividend payments to stockholders of **$21 million**, share repurchases of **$17 million**, cash dividends paid to noncontrolling interests of **$14 million**, and repayments of long-term debt of **$6 million**[122](index=122&type=chunk) - These payments were partially offset by proceeds from short-term borrowings of **$11 million** and proceeds from sales of common stock of **$3 million**[122](index=122&type=chunk) [Forward-Looking Information](index=27&type=section&id=Forward-Looking%20Information) This section highlights that the report contains forward-looking statements regarding future business performance, demand, liquidity, capital spending, regulatory developments, and litigation outcomes. It cautions that actual results could differ materially due to various risks and uncertainties, including industry competition, raw material volatility, economic conditions, and the ongoing impacts of the COVID-19 pandemic - This report contains "forward-looking statements" addressing expectations or projections about future business performance, demand for products, liquidity, capital spending, regulatory developments, cash requirements, and legal proceedings[140](index=140&type=chunk) - Actual results could differ materially due to risks such as industry capacity utilization, safety/health/environmental requirements, volatility in energy/raw material prices, adverse customer relationships, failure to achieve growth expectations, negative economic conditions, litigation, tax rates, and fluctuations in foreign currency/interest rates[123](index=123&type=chunk) - The duration or scope of the COVID-19 pandemic's negative impact cannot be estimated, and it has contributed to increased costs and decreased availability of labor and materials for construction projects[140](index=140&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=28&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Information about market risks for the period ended December 31, 2022, does not materially differ from that discussed in Item 7A of the 2022 10-K - Information about market risks for the period ended December 31, 2022, does not differ materially from that discussed under Item 7A of our 2022 10-K[123](index=123&type=chunk) [Item 4. Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures) As of December 31, 2022, management, including the principal executive and financial officers, concluded that the company's disclosure controls and procedures were effective. There were no material changes in internal controls over financial reporting during the quarter, with the internal controls of Tokai Carbon (Tianjin) Co. (acquired Feb 2022) excluded from the assessment - Our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2022[22](index=22&type=chunk) - There were no changes in our internal controls over financial reporting that occurred during our fiscal quarter ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting[22](index=22&type=chunk) - Internal controls over financial reporting at Tokai Carbon (Tianjin) Co., which was acquired on February 28, 2022, were excluded from the assessment for the period ended December 31, 2022[22](index=22&type=chunk) Part II. Other Information [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=29&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the company's equity security transactions, specifically focusing on issuer purchases of its common stock during the quarter ended December 31, 2022 [Issuer Purchases of Equity Securities](index=29&type=section&id=Issuer%20Purchases%20of%20Equity%20Securities) During the quarter ended December 31, 2022, Cabot Corporation repurchased a total of 152,968 shares of common stock at an average price of $71.89 per share. As of December 31, 2022, 4,100,166 shares remained available for repurchase under the existing authorization | Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs | | :-------------------------------------- | :------------------------------- | :--------------------------- | :------------------------------------------------------------------------------- | :----------------------------------------------------------------------------------------------------------- | | October 1, 2022 - October 31, 2022 | — | $— | — | 4,253,134 | | November 1, 2022 - November 30, 2022 | 70,861 | $72.64 | 70,861 | 4,182,273 | | December 1, 2022 - December 31, 2022 | 82,107 | $71.19 | 82,107 | 4,100,166 | | Total (for quarter ended Dec 31, 2022) | 152,968 | | 152,968 | | - On July 13, 2018, Cabot publicly announced that the Board of Directors authorized the Company to repurchase up to an additional **ten million shares** of its common stock, increasing the balance of shares available for repurchase at that time to approximately **eleven million shares**. The current authorization does not have a set expiration date[125](index=125&type=chunk) [Item 6. Exhibits](index=29&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including the Restated Certificate of Incorporation, By-laws, certifications of principal executive and financial officers, and Inline XBRL documents - Includes certifications of Principal Executive Officer (Exhibit 31.1), Principal Financial Officer (Exhibit 31.2), and both pursuant to 18 U.S.C. Section 1350 (Exhibit 32)[126](index=126&type=chunk) - Includes Inline XBRL Instance Document and Taxonomy Extension Documents (Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, 101.PRE)[126](index=126&type=chunk) [SIGNATURES](index=31&type=section&id=SIGNATURES) The report is signed on behalf of Cabot Corporation by Lisa M. Dumont, Vice President and Controller (Chief Accounting Officer), and Erica McLaughlin, Executive Vice President and Chief Financial Officer, on February 9, 2023 - Signed by Lisa M. Dumont, Vice President and Controller (Chief Accounting Officer)[25](index=25&type=chunk) - Signed by Erica McLaughlin, Executive Vice President and Chief Financial Officer[143](index=143&type=chunk) - Date of signing: February 9, 2023[25](index=25&type=chunk)[143](index=143&type=chunk)
Cabot (CBT) - 2022 Q4 - Annual Report
2022-11-23 19:31
| --- | --- | --- | |--------------------------------------|-------------------|-------------------------------------------| | | | | | Title of each class | Trading symbol(s) | Name of each exchange on which registered | | Common Stock, $1 par value per share | CBT | The New York Stock Exchange | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 ...
Cabot (CBT) - 2022 Q4 - Earnings Call Transcript
2022-11-08 19:27
Cabot Corporation (NYSE:CBT) Q4 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Steve Delahunt - Vice President of Investor Relations & Treasurer Sean Keohane - President & Chief Executive Officer Erica McLaughlin - Senior Vice President & Chief Financial Officer Conference Call Participants Anthony Mercandetti - Deutsche Bank James Cannon - UBS Jeff Zekauskas - JPMorgan Laurence Alexander - Jefferies Chris Kapsch - Loop Capital Operator Ladies and gentlemen, thank you for sta ...